New granted patents added to Hamlet BioPharma’s extensive patent portfolio in cancer and infection

Hamlet BioPharma’s extensive patent portfolio comprises 147 granted patents and 33
pending cases. Strategy regarding intellectual property rights, follow up and extension of
filed cases and patenting of new discoveries is overseen by the internationally established
legal firm Greaves-Brewster LLP, who have advised Hamlet BioPharma since the start.

We are delighted to announce the recent grant of three patents in the company’s portfolio.

1.  The Hamlet Mixing Method patent (CN 110650746) was granted in China on
   December 31st 2024.
   This patent to protects an improved method for the produc3on of HAMLET
   complexes, especially Alpha1H for clinical trials.
2. The Pol II inhibitors patent (IN 558357) was granted in India on January 21st 2025.
3. The Pol II inhibitors patent (AU 2017344453) was granted in Australia on March 6th
   2025.
   The Pol II inhibitors patents protect the molecule NlpD, which has shown
   strong therapeutic effects against bacterial infections in animal models. This
   protein inhibits excessive inflammation and accelerates bacterial clearance.

For more information, please contact

Catharina Svanborg, CEO and founder, +46 709 42 65 49
catharina.svanborg@hamletpharma.com

Ines Ambite, senior scientist, Lund University +46-762 08 89 58
Ines.Ambite@med.lu.se